Sustained release intraocular implants and methods for treating ocular vasculopathies

• US 8,506,986 B2
• Filed: 01/31/2008
• Issued: 08/13/2013
• Est. Priority Date: 04/30/2004
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Huang, Glenn T, Jackson, Brittany, Burke, James A., Lin, Ton, Hughes, Patrick M., Wheeler, Larry A., Donn, Rosy Sheng
• Primary Examiner(s): Sullivan, Daniel
• Assistant Examiner(s): PURDY, KYLE A
• Application Number:
  US12/024,014
• Publication Number:
  US 20080118548A1
• Time in Patent Office: 2,021 Days
• Field of Search: 514/249, 514/912
• US Class Current: 424/428
• CPC Class Codes: A61K 31/498 Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/204 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61L 2300/436 of receptors
• CPC Class Codes: A61L 2300/604 Biodegradation
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Claims

1. A method of treating glaucoma, the method comprising the step of placing in an eye a biodegradable intraocular implant comprising an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix, thereby treating the glaucoma, wherein:

a) said implant is an extruded filament;

b) said biodegradable polymer matrix consists of a poly(D,L-lactide) polymer having an inherent viscosity of about 0.3 dL/g and a 50;

50 poly(D,L-lactide-co-glycolide) polymer having an inherent viscosity of about 0.2 dL/g in a 1;

1 ratio;

c) said alpha-2 adrenergic receptor agonist is a brimonidine freebase;

d) said brimonidine freebase is about 40 weight percent of the implant; and

wherein

e) the duration of release of brimonidine freebase from the implant in vitro in phosphate buffered saline at 37°

C. is approximately 2 months.